Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Memantine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 known ✓ | Q05586 | 10/20 | 1.00 |
| ▸ | GRIN2A known ✓ | Q12879 | 10/20 | 1.00 |
| ▸ | GRIN2D known ✓ | O15399 | 9/20 | 1.00 |
| ▸ | GRIN3B known ✓ | O60391 | 9/20 | 1.00 |
| ▸ | GRIN2B known ✓ | Q13224 | 9/20 | 1.00 |
| ▸ | GRIN2C known ✓ | Q14957 | 9/20 | 1.00 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Memantine SCHEMBL2689 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL5606188 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL12959066 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL13198606 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL2688 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL23327176 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL2182056 | 0.97 | GRIN1 (0.95) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL1659626 | 0.97 | GRIN1 (0.95) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL3053 | 0.97 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL25223076 | 0.97 | GRIN1 (0.95) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016759-A1 | TRANSDERMAL DELIVERY SYSTEM WITH A MICROPOROUS MEMBRANE HAVING SOLVENT-FILLEDPORES | CORIUM, LLC | 2024-01-18 | — | — | US | disclosed |
| US-20230172902-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | TRAN LLOYD HUNG LOI (US) | 2023-06-08 | — | — | US | disclosed |
| US-10016372-B2 | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery | CORIUM INTERNATIONAL, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180028461-A1 | TRANSDERMAL DELIVERY SYSTEMS WITH PHARMACOKINETICS BIOEQUIVALENT TO ORAL DELIVERY | COLUMBUS INVESTMENT HOLDINGS SA (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20180028467-A1 | TRANSDERMAL DELIVERY SYSTEMS WITH PHARMACOKINETICS BIOEQUIVALENT TO ORAL DELIVERY | COLUMBUS INVESTMENT HOLDINGS SA (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20180028466-A1 | MEMANTINE TRANSDERMAL DELIVERY SYSTEMS | CORIUM PHARMA SOLUTIONS, INC. | 2018-02-01 | — | — | US | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100099714-A1 | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| WO-2008139984-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008111590-A2 | AMPA AND NMDA RECEPTOR ANTAGONISTS FOR NEURODEGENERATIVE DISEASES | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-18 | — | — | WO | disclosed |
| US-20080182908-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MEMANTINE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-07-31 | — | — | US | disclosed |
| US-20080182908-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MEMANTINE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | GRIN1 1/4885GRIN2A 2/4885GRIN2D 8/4885 |
| US-20100099714-A1 | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases | GRIN1, GRIN2A, GRIN3A | GRIN1 1/4885GRIN2A 2/4885GRIN2D 9/4885 |
| US-20230172902-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | ACE, ACE2, LPO | GRIN1 3717/4885GRIN2A 3538/4885GRIN2D 3674/4885 |
| US-20080182908-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MEMANTINE | PSEN2, PSEN1, NEFM | GRIN1 9/4885GRIN2A 5/4885GRIN2D 13/4885 |
| US-10016372-B2 | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery | CYP1A2, CYP2A7, CYP2A13 | GRIN1 3898/4885GRIN2A 3087/4885GRIN2D 4104/4885 |
| US-20180028466-A1 | MEMANTINE TRANSDERMAL DELIVERY SYSTEMS | PSEN1, PSEN2, ACHE | GRIN1 19/4885GRIN2A 9/4885GRIN2D 54/4885 |
| US-20180028467-A1 | TRANSDERMAL DELIVERY SYSTEMS WITH PHARMACOKINETICS BIOEQUIVALENT TO ORAL DELIVERY | CYP1A2, CYP2A7, CYP2A13 | GRIN1 3898/4885GRIN2A 3087/4885GRIN2D 4104/4885 |
| US-20240016759-A1 | TRANSDERMAL DELIVERY SYSTEM WITH A MICROPOROUS MEMBRANE HAVING SOLVENT-FILLEDPORES | CD69, CUTA, PGRMC2 | GRIN1 2206/4885GRIN2A 1774/4885GRIN2D 2636/4885 |
| US-20180028461-A1 | TRANSDERMAL DELIVERY SYSTEMS WITH PHARMACOKINETICS BIOEQUIVALENT TO ORAL DELIVERY | CYP1A2, CYP2A7, CYP2A13 | GRIN1 3898/4885GRIN2A 3087/4885GRIN2D 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.